ReviewJournal of contemporary brachytherapy2018
Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results.
Review in Journal of contemporary brachytherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Role of fallopian tube and cervical canal occlusion in preventing intra-operative tumour spillage in early endometrial cancer- a pilot study.World journal of surgical oncology · 2025Trial
- Effect of Lactobacillus delbrueckii subsp. lactis on vaginal radiotherapy for gynecological cancer.Scientific reports · 2023Trial
- High-dose-rate vaginal brachytherapy for treatment of recurrent high-grade vaginal intraepithelial neoplasia.La Radiologia medica · 2026Article
- Exercise and physiotherapy for enhancing muscle strength, managing lower-limb lymphedema, and improving sexual function in the treatment and survivorship of gynecological cancers.Frontiers in oncology · 2026Review
- Microbiome-host interactions in locally advanced cervical cancer: the impact on chemoradiotherapy treatment outcomes and toxicity.Frontiers in immunology · 2026Review
- High-Dose-Rate Brachytherapy for Vaginal Rhabdomyosarcoma (RMS): Lessons Learned at a Single Institution.International journal of radiation oncology, biology, physics · 2025Article
- Addressing sexual health needs in gynecological cancer survivors: insights from a tertiary cancer center in Jordan.Frontiers in oncology · 2025Article
- Sexual dysfunction and quality of life in cervical and endometrial cancer patients before and after low-dose-rate brachytherapy: a cohort study.Frontiers in medicine · 2025Article
- The Cost-Effectiveness of Sentinel Lymph Node Mapping in High-Risk Endometrial Cancer.Cancers · 2024Article
- A novel multi-channel applicator with a U-shaped channel for vaginal intracavity brachytherapy.Journal of applied clinical medical physics · 2024Article
- Hyaluronic acid to manage radiotoxicities in gynecological cancer patients: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Characterisation of a Silicon Photomultiplier Based Oncological Brachytherapy Fibre Dosimeter.Sensors (Basel, Switzerland) · 2024Article
- Pelvic floor muscle training delivered via telehealth to treat urinary and/or faecal incontinence after gynaecological cancer surgery: a single cohort feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Quality of life and sexual functioning among endometrial cancer patients treated with one week adjuvant high-dose-rate vaginal brachytherapy schedule.Journal of contemporary brachytherapy · 2022Article
- Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series.Journal of contemporary brachytherapy · 2021Article
- Correlation of total reference air-kerma (TRAK) to prescription isodose surface volume in vaginal cylinder high-dose-rate brachytherapy.Journal of contemporary brachytherapy · 2021Article
- Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients - in view of the recent evidence.Journal of contemporary brachytherapy · 2021Review
- Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: a systematic review.Journal of contemporary brachytherapy · 2021Review
- Sexual Health Dysfunction After Radiotherapy for Gynecological Cancer: Role of Physical Rehabilitation Including Pelvic Floor Muscle Training.Frontiers in medicine · 2021Review
- One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients.Journal of contemporary brachytherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate vaginal toxicity (primary endpoint) and local control (secondary endpoint) in patients with endometrial cancer who underwent primary surgery and adjuvant high-dose-rate (HDR) endovaginal brachytherapy (BT). MATERIAL AND
methodsIn September 2017, the authors conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus, and Cochrane library. In this systematic review, the authors included randomized trials, non-randomized trials, prospective studies, retrospective studies, and cases. The time period of the research included articles published from September 1997 to September 2017.
resultsAcute endovaginal toxicity occurred in less than 20.6% and all acute toxicities were G1-G2. The most common early side effects due to HDR-BT treatment were vaginal inflammation, vaginal irritation, dryness, discharge, soreness, swelling, and fungal infection. G1-G2 late toxicity occurred in less than 27.7%. Finally, G3-G4 late vaginal occurred in less than 2%. The most common late side effects consisted of vaginal discharge, dryness, itching, bleeding, fibrosis, telangiectasias, stenosis, short or narrow vagina, and dyspareunia.
conclusionsThe data suggest that HDR endovaginal brachytherapy, with or without chemotherapy, is very well tolerated with low rates of acute and late vaginal toxicities. Further prospective studies with higher numbers of patients and longer follow-up are necessary to evaluate acute and late toxicities after HDR endovaginal brachytherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.